Questions remain over safety and effectiveness of oseltamivirBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e467 (Published 17 January 2012) Cite this as: BMJ 2012;344:e467
- Deborah Cohen
Two years after the pharmaceutical giant Roche promised the BMJ that it would release key trial data on oseltamivir (Tamiflu) for independent scrutiny, the safety and effectiveness of this anti-influenza drug remain uncertain, a new meta-analysis by the Cochrane collaboration says.
Cochrane researchers set out to test Roche’s claim that the drug prevented complications and reduced the number of people needing hospital treatment. Their report says that Roche’s refusal to provide full access to all its data leaves critical questions about how well the drug works unresolved (BMJ 2012;344:d7898, doi:10.1136/bmj.d7898).
Roche maintains that it provided the Cochrane researchers with enough information …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial